OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🔴 Outlook Therapeutics is trading 27.16% down today after pricing a discounted $55 million stock-and-warrant offering
Outlook Therapeutics is trading at $0.80 (-27.16%) after pricing 55.6 million shares with accompanying warrants at $0.99, below the $1.10 August 12 close. -...
🔴 Outlook Therapeutics is trading 14.55% down in pre-market after pricing a $55 million offering at $0.99
Outlook Therapeutics is trading 14.55% down in pre-market at $0.94 after announcing a $55.0 million underwritten public offering priced at $0.99 per...
Outlook Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
Outlook Therapeutics is projected to report consensus revenue of approximately $0.97 million and an EPS loss of $0.09, with the stock currently trading at...
Outlook Therapeutics reports $11.2M third quarter 2026 cash with runway into September
Outlook Therapeutics reported a preliminary cash balance of approximately $11.2 million for its third quarter ended June 30, 2026. Despite the July 2026 FDA...
🔴 Outlook Therapeutics is trading 11.81% down in after-hours trading with no clear company-specific announcement identified
Outlook Therapeutics is trading 11.81% down at $0.97 after no clear company-specific announcement was identified for August 12, 2026. - The decline is...
🔴 Outlook Therapeutics is trading 5% down today with no clear catalyst
Outlook Therapeutics is trading 5.22% down at $1.09 after no new company-specific announcement was identified for August 11, 2026. - The July 24 FDA approval...
🟢 Outlook Therapeutics is trading 10.72% up today following July 24 FDA approval of LYTENAVA
Outlook Therapeutics is trading at $1.13, up +10.72%, following the July 24 FDA approval of LYTENAVA for wet AMD. - LYTENAVA became the first FDA-approved...
🟢 Outlook Therapeutics is trading 7.35% up today after July 24 FDA approval of LYTENAVA
Outlook Therapeutics is trading 7.35% up now at $1.09, with the move appearing primarily technical and sentiment-driven following the July 24 FDA approval of...
Outlook Therapeutics Won Its FDA Bet — But Can a Cash-Strapped Biotech With $7.7 Million Actually Launch a Drug?
Shares of Outlook Therapeutics slid 7.6% to $0.90 on Thursday as traders cashed in gains from a volatile post-approval rally, raising a harder question:...
🔴 Outlook Therapeutics is trading 5.6% down today
Outlook Therapeutics is trading at $0.97, down -5.58%, with no new negative company-specific catalyst identified for August 6, 2026. - Outlook Therapeutics...
🟢 Outlook Therapeutics is trading 5.7% up today amid biotech sector rebound
Outlook Therapeutics is trading 5.7% up today at $1.01 as shares rebound alongside a broader lift in the biotechnology sector. • The stock continues to...
🟢 Outlook Therapeutics is trading 5.7% up today as it rebounds amid broader biotech sector strength
Outlook Therapeutics is trading 5.7% up at $0.97 today as it rebounds alongside a strong biotech sector following yesterday’s pullback and its late-July...
🔴 Outlook Therapeutics is trading 7.7% down today as it extends a pullback from its recent FDA-driven rally
Outlook Therapeutics is trading at $0.90 (-7.65%) today as the stock extends a pullback from its late-July surge. • The decline is primarily driven by...
🔴 Outlook Therapeutics is trading 10.2% down today on profit-taking following its FDA-driven rally
Outlook Therapeutics is trading 10.2% down at $0.93 on profit-taking and consolidation following a multi-day rally driven by recent FDA approval news. • The...
🔴 Outlook Therapeutics is trading 5.3% down today on profit-taking after a multi-day post-FDA approval rally
Outlook Therapeutics is trading 5.3% down at $0.98 as the stock enters a period of consolidation following a significant multi-day rebound. • The pullback...
🟢 Outlook Therapeutics is trading 5.5% up today as rebound continues after LYTENAVA FDA approval and insider buying
• Outlook Therapeutics is trading 5.5% up at $1.05 as it extends recovery following the FDA approval of its wet AMD therapy, LYTENAVA. • The stock is building...
🟢 Outlook Therapeutics is trading 19% up today as buyers return following a sharp post-FDA approval selloff
Outlook Therapeutics is trading 19% up at $1.08 as buyers step back in following a sharp post-FDA approval selloff in its wet AMD therapy, LYTENAVA. • The...
🟢 Outlook Therapeutics is trading 5% up today as investors bargain hunt after post-FDA approval selloff
Outlook Therapeutics is trading 5% up at $0.95 as investors step back in following a sharp two-day selloff that followed the FDA approval of its wet AMD...
🔴 Outlook Therapeutics Continues Decline with 16% Drop as Investors Take Profits Following FDA Approval of LYTENAVA
• Outlook Therapeutics received FDA approval for its wet age-related macular degeneration (wet AMD) drug, LYTENAVA, on July 27, 2026. • The stock experienced...
🔴 Outlook Therapeutics is trading 9.9% down today on profit-taking after FDA-driven rally
Outlook Therapeutics is trading 9.9% down today at $0.94 as traders lock in profits following a sharp FDA approval-driven rally in its wet AMD program. • The...